Duligotuzumab Biosimilar - Research Grade

Human

ERBB3

>1mg/ml

IgG1 - kappa

CHO Cells

Patritumab Biosimilar - Research Grade (ICH5206), Elgemtumab Biosimilar - Research Grade (ICH5513), Lumretuzumab Biosimilar - Research Grade (ICH5660), Nezutatug Biosimilar - Research Grade (ICH5710), Seribantumab Biosimilar - Research Grade (ICH5854)

https://www.imgt.org/mAb-DB/

ICH3002

P21860

Blue ice

This is a research-grade, unconjugated non-therapeutic recombinant analog of duligotuzumab, supplied for research use only (not for human or veterinary use). Duligotuzumab is notable as a dual-action antibody engineered to engage two receptors in the ErbB/HER family, and the analog is built around its receptor-binding activity for laboratory work. As a human IgG1/kappa protein produced recombinantly, it is useful as a defined, reproducible reagent for functional and preclinical studies: receptor-binding and neutralization assays, blocking of ligand-driven signaling, positive/isotype controls, epitope and competition experiments, and as a benchmarking standard alongside other anti-ErbB antibodies. The IgG1 backbone also makes it suitable for ADCC readouts and as a scaffold in antibody-drug-conjugate and bispecific development workflows. It is offered at research-grade low endotoxin (<1 EU/mg), with ultra-low endotoxin (<0.5 EU/mg) and bulk milligram-to-gram quantities available to support in-vitro assays and preclinical model standards. Being a non-therapeutic analog, it is intended purely for method development, characterization, and comparability rather than clinical application. ERBB3 (HER3, UniProt P21860) is a member of the EGFR/ErbB receptor tyrosine kinase family. It has an extracellular ligand-binding region, a single transmembrane domain, and a pseudokinase domain that is catalytically impaired, so ERBB3 cannot signal effectively on its own. Upon binding its ligands, the neuregulins (heregulins, NRG1/NRG2), ERBB3 heterodimerizes with partners, most potently ERBB2 (HER2) and also EGFR. Because its cytoplasmic tail carries multiple docking sites for the p85 subunit of PI3K, ERBB3-containing dimers are exceptionally strong activators of the PI3K/AKT survival and growth pathway, and also feed into MAPK signaling. ERBB3 up-regulation and neuregulin autocrine loops are recognized mechanisms of resistance to EGFR- and HER2-directed therapies, which is why ERBB3 and its EGFR/HER2 partners are prominent oncology targets.

Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3, HER3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks